About CloSys
The Company is currently conducting a FDA IDE approved randomized trial on the CloSys HD with completion expected in early 2012. Prior clinical investigation includes a European feasibility study in 2008, and a US FDA IDE feasibility study in 2010.
CloSys Corporation is a private clinical stage company focused on the development of the CloSys Hemostatic Device (HD), a quick, reliable, and safe natural closure system for vascular access sites.
Learn more about CloSys.
The CloSys Team
Andrea Fenton Abbs
Clinical Study Director, JAbbs CRO
C.J. Schweich M.D.
Medical Director U.S. Clinical Trial
Mary Lach CPA
CFO
Mary Beth Henderson
Lead Regulatory Consultant (RCRI)
Karol Nowakowski
Founder and Director
Gervaise Wilhelm
President and CEO
Board of Directors
John Frobenius
Chair
Bruce Johnson
Lee Zachman
Karol Nowakowski and Gervaise Wilhelm also serve on the board. Their bios are found in the CloSys Team section.
Medical Advisory Board
Spencer King III MD
Cardiology
Robert Schwartz MD
Cardiology
Byron Simmons MD
Hematopathology
Kendall Price MD
Hematopathology